Interview with the CEO: Trovagene, Inc. (TROV)

Healthcare >> CEO Interviews >> December 4, 2014

Dr. Antonius Schuh is CEO at Trovagene, Inc., a molecular diagnostics company specializing in noninvasive diagnostic solutions based on cell-free DNA. The company has developed its precision cancer monitoring platform, which detects and quantifies circulating tumor DNA — ctDNA — in blood and urine to track the driver mutations of a patient’s tumor to monitor treatment response, and resistance to therapy. Dr. Schuh has been CEO of Trovagene since October 2011. He has held numerous executive positions at leading life science and molecular diagnostics companies, including Chairman of the board and CEO of Sorrento Therapeutics; CEO of AviaraDx, Inc., now bioTheranostics, Inc.; CEO of Arcturus Bioscience Inc.; and President and CEO of Sequenom, Inc. Dr. Schuh is also a director of DioGenix, Inc., and Gensignia, Inc., both privately held molecular diagnostics companies, and a managing partner of GSV LLC, a life sciences investment and advisory firm. He is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany. Profile

TWST: I’d like to begin by asking you to provide a brief overview of Trovagene’s business.

Dr. Schuh: Trovagene is a molecular diagnostic company that noninvasively detects

Join for free to read a longer excerpt or purchase this article

Interview with the CEO: Trovagene, Inc. (TROV)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO: Trovagene, Inc. (TROV)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS